ArticleCureus2025
Pathologic Findings From Conization as Predictors of Residual Disease in Stage IA2 Cervical Cancer: Implications for Fertility-Preserving Surgery With Sentinel Lymph Node Biopsy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConization is a standard fertility-preserving treatment for stage IA1 cervical cancer; however, its role in stage IA2 disease remains controversial due to limited supporting evidence. This study aimed to evaluate the feasibility of conization with or without sentinel lymph node (SLN) biopsy as a fertility-sparing strategy in patients with stage IA2 cervical cancer.
methodsWe retrospectively analyzed 20 patients diagnosed with stage IA2 cervical cancer based on conization pathology who subsequently underwent modified radical or radical hysterectomy or trachelectomy with SLN biopsy at Kagoshima University Hospital between March 2014 and December 2023. SLN mapping was performed using a hybrid technique combining technetium-99m and indocyanine green. Residual tumor presence in hysterectomy specimens and associated clinicopathologic factors were evaluated.
resultsThe median age was 45 years. Histologic subtypes included squamous cell carcinoma (75%) and adenocarcinoma (25%). SLN mapping was successfully performed bilaterally in all patients (100%), with no SLN metastases detected. Residual tumor was identified in eight patients (40%). Positive endocervical curettage (ECC) was significantly associated with residual tumor (OR = 3.38, 95% CI: 1.31-8.76, p = 0.035). Notably, no residual tumor was observed in patients with both negative ECC and negative endocervical margins. Among the five patients who underwent trachelectomy, all preserved their fertility potential during the follow-up period, and no recurrences were observed during a median follow-up of 45 months.
conclusionIn patients with stage IA2 cervical cancer, positive ECC and adenocarcinoma histology were significantly associated with residual tumor in the final hysterectomy specimen. Importantly, no residual tumor was observed in patients with both negative ECC and negative endocervical margin, particularly among those with squamous cell carcinoma. These findings suggest that for highly selected patients, especially those with squamous histology, conization ± SLN biopsy may represent a safe and less invasive fertility-preserving alternative to trachelectomy. Further prospective studies are needed to confirm oncologic safety and define appropriate selection criteria, particularly for cases of adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.